The Role of Bioactive Lipids and Statins in COVID-19 Disease and Their Use in the Therapeutic Approach. Are These Effective?

COVID-19 disease constitutes a significant threat to human existence worldwide due to the increased transmissibility, morbidity and mortality caused by the still unknown SARS-COV2 virus. A critical issue is the lack of effectiveness of drug options. In our research, a literature review, we explore the role of bioactive lipids and statins can play, as a main or adjunctive treatment in the COVID-19. We reviewed 150 articles in the Databases (PubMed/MEDLINE, Google Scholar, Embassy and Cochrane) relatives of the use of bioactive lipids and statins in severe COVID-19 disease and we selected 117 articles that fit with our research question. So, our research constitutes a bibliography review of 117 articles, finally. The administration of exogenous bioactive lipids (BALs), Omega 3 EPA, DHA supplements induces the suppression of pro-inflammatory cytokines, the prevention of cytokine storm and enhancing the therapeutic benefit by accelerating recovery. Therefore, they potentially reduce the need for ICU hospitalization and the number of intensive care unit days of stay, accelerating recovery thus also numerically reducing critical cases. The possible harms of lipids should be considered. There are positive and negative effects regarding the use of statins. According to the literature, Statins offer beneficial effects on COVID-19 disease. For de novo statin use in COVID-19 patients, the Benefit/Risk ratio should be taken into account. In conclusion, although lipids and statins seem to benefit patients with severe COVID-19 disease, nevertheless, more double blind randomized studies are needed to determine their safety and efficacy profile.

Lipid metabolism analysis in esophageal cancer and associated drug discovery

Esophageal cancer is an upper gastrointestinal malignancy with a bleak prognosis.It is still being explored in depth due to its complex molecular mechanisms of occurrence and development.Lipids play a crucial role in cells by participating in energy supply,biofilm formation,and signal transduction processes,and lipid metabolic reprogramming also constitutes a significant characteristic of malignant tumors.More and more studies have found esophageal cancer has obvious lipid metabolism abnormalities throughout its beginning,progress,and treatment resistance.The inhibition of tumor growth and the enhancement of antitumor therapy efficacy can be achieved through the regulation of lipid metabolism.Therefore,we reviewed and analyzed the research results and latest findings for lipid metabolism and associated analysis techniques in esophageal cancer,and comprehensively proved the value of lipid metabolic reprogramming in the evolution and treatment resistance of esophageal cancer,as well as its significance in exploring potential therapeutic targets and biomarkers.

Focus on LPA signaling:a promising therapeutic target to foster regeneration in immune-mediated neuropathies

Lysophospholipids are metabolites of glycerophospholipids and sphingolipids that are commonly found as lipid constituents of cell membranes.In addition to their function as structural membrane components,certain members of the lysophospholipid family have considera ble cell signaling pro perties.Sphingosine-1-phosphate(S1P) and lysophosphatidic acid(LPA)represent the two major bioactive members of the lysophospholipid family that address specific G-protein cou pled receptors.

Lipid dysregulation in hepatitis C virus, and impact of statin therapy upon clinical outcomes

The hepatitis C virus(HCV) is one of the most common causes of chronic liver disease and the leading indication for liver transplantation worldwide. Every aspect of the HCV life cycle is closely tied to human lipid metabolism. The virus circulates as a lipid-rich particle, utilizing lipoprotein cell receptors to gain entry into the hepatocyte. It has also been shown to upregulate lipid biosynthesis and impair lipid degradation, resulting in significant intracellular lipid accumulation and circulating hypocholesterolemia. Patients with chronic hepatitis C(CHC) are at increased risk of hepatic steatosis, fibrosis, and cardiovascular disease including accelerated atherosclerosis. HMG Co A Reductase inhibitors, or statins, have been shown to play an important role in the modulation of hepatic steatosis and fibrosis, and recent attention has focused upon their potential therapeutic role in CHC. This article reviews the hepatitis C viral life cycle as it impacts host lipoproteins and lipid metabolism. It then describes the pathogenesis of HCV-related hepatic steatosis, hypocholesterolemia and atherosclerosis, and finally describes the promising anti-viral and anti-fibrotic effects of statins, for the treatment of CHC.

Influences of blood lipids on the occurrence and prognosis of hemorrhagic transformation after acute cerebral infarction: a case-control study of 732 patients

Background: To study the influence of blood lipid levels on hemorrhagic transformation(HT) and prognosis after acute cerebral infarction(ACI).Methods: Patients with ACI within 72 h of symptoms onset between January 1 st, 2015, and December 31 st, 2016, were retrospectively analyzed. Patients were divided into group A(without HT) and group B(HT). The outcomes were assessed after 3 months of disease onset using the modified Rankin Scale(m RS). An m RS score of 0–2 points indicated excellent prognosis, and an m RS score of 3–6 points indicated poor prognosis.Results: A total of 732 patients conformed to the inclusion criteria, including 628 in group A and 104 in group B. The incidence of HT was 14.2%, and the median onset time was 2 d(interquartile range, 1–7 d). The percentages of patients with large infarct size and cortex involvement in group B were 80.8% and 79.8%, respectively, which were both significantly higher than those in group A(28.7 and 33.4%, respectively). The incidence rate of atrial fibrillation(AF) in group B was significantly higher than that in group A(39.4% vs. 13.9%, P<0.001). The adjusted multivariate analysis results showed that large infarct size, cortex involvement and AF were independent risk factors of HT, while total cholesterol(TC) was a protective factor of HT(OR=0.359, 95% CI 0.136–0.944, P=0.038). With every 1 mmol/L reduction in normal TC levels, the risk of HT increased by 64.1%. The mortality and morbidity at 3 months in group B(21.2% and 76.7%, respectively) were both significantly higher than those in group A(8.0% and 42.8%, respectively). The adjusted multivariate analysis results showed that large infarct size(OR=12.178, 95% CI 5.390–27.516, P<0.001) was an independent risk factor of long-term unfavorable outcomes, whereas low-density lipoprotein cholesterol(LDL-C) was a protective factor(OR=0.538, 95% CI 0.300–0.964, P=0.037). With every 1 mmol/L reduction in normal LDL-C levels, the risk of an unfavorable outcome increased by 46.2%. Major therapies, including intravenous recombinant human tissue plasminogen activator(r TPA), intensive lipid-lowering statins and anti-platelets, were not significantly related to either HT or long-term, post-ACI poor prognosis.Conclusions: For patients with large infarct sizes, especially those with cortex involvement, AF, or lower levels of TC, the risk of HT might increase after ACI. The risk of a long-term unfavorable outcome in these patients might increase with a reduction in LDL-C.

Lipid metabolism of hepatocellular carcinoma impacts targeted therapy and immunotherapy

Hepatocellular carcinoma(HCC)is a common malignant tumor that affecting many people's lives globally.The common risk factors for HCC include being overweight and obese.The liver is the center of lipid metabolism,synthesizing most cholesterol and fatty acids.Abnormal lipid metabolism is a significant feature of metabolic reprogramming in HCC and affects the prognosis of HCC patients by regulating inflammatory responses and changing the immune microenvironment.Targeted therapy and immunotherapy are being explored as the primary treatment strategies for HCC patients with unresectable tumors.Here,we detail the specific changes of lipid metabolism in HCC and its impact on both these therapies for HCC.HCC treatment strategies aimed at targeting lipid metabolism and how to integrate them with targeted therapy or immunotherapy rationally are also presented.

The Impact of Statin Intolerance in Lipid Clinic Patients

Context: Cardiovascular disease is a very common and serious problem in the western world. Statin drug therapy is used in primary, secondary prevention and familial hypercholesterolemia. However, these are frequently associated with adverse effects, causing poor adherence and thus putting patients at risk for future cardiovascular events. Aim: The objective of this study was to review the statin intolerance in lipid patients and to assess the impact of alternative lipid lowering therapy on lipid parameters and cardiovascular outcome in statin intolerant patients. Methodology: 50 patients attending the out-patient lipid clinic of our hospital with statin intolerance were identified. Clinical data on the study patients were gathered retrospectively relating to statin intolerance and the clinical effectiveness of alternative lipid lowering therapy on lipid parameters and cardiovascular outcome. Results: Rosuvastatin was the most intolerable whereas pravastatin or fluvastatin was the most tolerable statin in our study patients. Myalgia was the commonly reported adverse effect of statin. The low dose statin monotherapy or combination of low dose statin and ezetemibe was the most tolerable alternative lipid lowering therapy in statin intolerant patients. After an average period of 10 months of initiation of alternative lipid lowering therapy;combination of low dose statin plus ezetimibe showed the largest reduction in serum total cholesterol and low-density lipoprotein (LDL) cholesterol levels. Conclusions: Pravastatin should be preferred in statin intolerant patients. A combination of low dose statin plus ezetimibe appeared to be the most tolerable and clinically effective therapy in statin intolerant patients.

血清脂质相关指标与乳腺癌关系的研究进展

脂代谢紊乱与乳腺癌的发生发展及预后密切相关。探索血清脂质相关指标、降脂药物对乳腺癌发病及预后的影响,有助于寻找乳腺癌新的生化标志物,发现新的治疗靶点并对其进行更精准的个体化治疗。本文通过查阅相关文献,就血清脂质相关指标与乳腺癌之间的关系做一综述,为深入研究乳腺癌的发病机制及乳腺癌的预防、诊断及治疗提供新的方向。

他汀类药物治疗子宫内膜异位症的研究进展

子宫内膜异位症(简称“内异症”)是具有活性的内膜细胞种植在子宫以外的部位而形成的一种常见的妇科内分泌疾病,影响到全球10%~15%的育龄期女性,与欧美白人女性相比,亚洲女性患内异症的风险增加了9倍。内异症不仅会引起慢性盆腔痛、痛经、性交痛等疼痛症状,还会引起不孕,进而导致患者出现疲劳、高度敏感和焦虑的情绪,降低其生活质量。随着我国人口老龄化加剧和女性生育年龄推迟,解决如内异症这种影响女性生育力的妇科内分泌疾病迫在眉睫。近年来研究表明,内异症患者血清脂质代谢异常、患心血管疾病的风险增加,同时降血脂的他汀类药物可在细胞和动物水平抑制内异症的进展,少量临床研究也表明他汀类药物对内异症的治疗具有积极作用。本文将综述内异症与心血管疾病关系的研究,并从细胞、动物、人体三个层面综述他汀类药物治疗内异症的研究进展。

糖尿病患者血脂管理及干预策略研究进展

糖尿病(DM)患者常伴有血脂异常,这将增加心血管疾病的发病风险。降脂治疗、生活方式干预等能够显著改善DM患者的血脂异常状况,降低心血管事件的发生风险,从而让DM患者在临床上受益。本研究查阅相关文献,阐述了血脂管理及其干预策略的研究进展,旨在为临床治疗提供参考。

中等强度他汀类药物调脂治疗效果对男性冠心病患者肠道菌群的影响分析

目的研究中等强度他汀类药物调脂治疗效果对男性冠心病患者肠道菌群的影响。方法选取2019年1月至2022年1月于九江市第一人民医院接受中等强度他汀类药物治疗的60例男性冠心病患者作为研究对象,根据调脂效果分为达标组[低密度脂蛋白胆固醇(LDL-C)<1.8mmol/L,n=36]与未达标组(LDL-C≥1.8mmol/L,n=24)。比较两组血糖血脂指标、肠道菌群Alpha多样性、肠道益生菌数量、肠道致病菌数量及不良反应发生情况。结果治疗后,达标组甘油三脂(TG)、总胆固醇(TC)、LDL-C水平均低于未达标组,差异有统计学意义(P<0.05),但两组高密度脂蛋白胆固醇、空腹血糖、糖化血红蛋白A1c水平比较差异无统计学意义。治疗后,达标组肠道菌群操作分类单元(OTU)、Spannon指数高于未达标组,肠道菌群Simpson指数低于未达标组,差异有统计学意义(P<0.05)。治疗后,达标组肠道益生菌菌群(双歧杆菌、乳酸菌、拟杆菌)数量多于未达标组,肠道致病菌菌群(大肠杆菌、梭菌、链球菌)数量少于未达标组,差异有统计学意义(P<0.05)。治疗后,达标组不良反应发生率低于未达标组,差异有统计学意义(P<0.05)。结论中等强度他汀类药物调脂治疗效果达标,能增加肠道菌群多样性及益生菌数量,减少致病菌数量,降低胃肠道不良反应发生率。

血脂水平与肿瘤相关性的研究进展

血脂对维持正常的生理稳态至关重要,血脂水平与心血管疾病及癌症的发生、发展和转移密切相关。他汀类药物是常用于调节血脂、抵抗炎症、保护血管内皮和抗血小板凝聚等方面的药物,其抗肿瘤功效和作用也正受到广泛关注。该文对血脂水平与4种常见肿瘤的关系,以及他汀类药物调节血脂水平、抗肿瘤的作用机制进行了综述。他汀类药物在发挥调节血脂水平作用的同时,有望作为肿瘤药物在肿瘤治疗中发挥更大的作用。

氨氯地平联合阿托伐他汀钙片治疗高血压合并冠心病的临床疗效

目的 分析氨氯地平联合阿托伐他汀钙片对高血压合并冠心病患者的康复所起到的积极作用。方法 78例高血压合并冠心病患者,采用随机数字表法分为对照组与观察组,每组39例。对照组采用氨氯地平治疗,观察组采用氨氯地平联合阿托伐他汀钙片治疗。对比两组血压、血脂、临床治疗效果、并发症发生率、自我护理能力[自我护理能力量表(ESCA)评分]及生活质量水平[生活质量量表(QOL)评分]。结果 治疗后,两组收缩压和舒张压均较治疗前降低,且观察组收缩压(122.23±10.74)mm Hg(1 mm Hg=0.133 kPa)和舒张压(87.58±9.86)mm Hg低于对照组的(137.69±12.56)、(95.86±8.05)mm Hg,差异显著(P<0.05)。观察组总胆固醇(3.06±0.36)mmol/L、低密度脂蛋白胆固醇(1.51±0.21)mmol/L、甘油三酯(1.54±0.14)mmol/L均低于对照组的(4.14±0.74)、(1.87±0.16)、(2.03±0.06)mmol/L,高密度脂蛋白胆固醇(1.54±0.14)mmol/L高于对照组的(1.25±0.13)mmol/L,差异显著(P<0.05)。观察组治疗总有效率94.87%显著高于对照组的74.36%,差异显著(P<0.05)。观察组不良反应发生率7.69%显著低于对照组的28.21%,差异显著(P<0.05)。治疗后,观察组ESCA评分(123.45±12.63)分及QOL评分(57.56±6.13)分高于对照组的(108.23±10.65)、(48.52±6.22)分,差异显著(P<0.05)。结论 氨氯地平联合阿托伐他汀钙片用于高血压合并冠心病治疗中,取得了良好的疾病治疗效果。

他汀不耐受的临床诊断与处理中国专家共识

他汀不耐受是指患者服用他汀类药物后出现一种或多种他汀类药物相关不良反应,减量或停用他汀类药物可改善,重启后再次出现的临床现象。他汀不耐受的相关报道并非少见,但真实世界中他汀不耐受的临床诊断与处理存在一定的困惑或误区,包括缺乏统一的定义和诊断标准、诊断的把握度偏宽、处理策略欠科学等问题,这在一定程度上阻碍了他汀类药物的科学、合理地使用。据此,本共识全面复习全球他汀不耐受相关研究数据,参考国外他汀不耐受相关指南与共识,提出适合我国人群的他汀不耐受的基本定义,并推荐相应的诊断标准及处理策略,以期改善我国人群他汀类药物的临床应用现状,进而提高动脉粥样硬化性心血管疾病的防治水平。

基于中医体质学说观察中药祛湿导滞方干预痰湿质患者脂代谢异常的临床疗效

目的探讨中药祛湿导滞方干预痰湿型体质患者脂代谢异常的临床疗效及安全性。方法将2021年1月至2023年1月102例门诊患者按照随机数字表分为祛湿导滞方治疗组62例,口服阿托伐他汀片对照组60例,干预4周后,观察两组三酰甘油(triglyceride,TG)、总胆固醇(total cholesterol,TC)、低密度脂蛋白胆固醇(low-density lipoprotein cholesterol,LDL-C)、高密度脂蛋白胆固醇(high-density lipoprotein cholesterol HDL-C)、中医证候评分、临床疗效等指标。结果治疗后,两组中医证候评分、TC、LDL-C、TG血含量均降低,HDL-C含量均升高,与对照组比较,治疗组改善的更显著(P<0.05)。对照组总有效率80.0%;治疗组总有效率95.2%,与对照组比较,差异有统计学意义(P<0.05)。治疗组痰湿体质转化分明显低于治疗前和对照组(P<0.05)。结论中药祛湿导滞方能显著降低痰湿体质型患者脂代谢异常引起的TC、TG、LDL-C水平,提高HDL-C水平,安全有效。

ABCB1基因C3435T多态性对他汀类药物降脂疗效影响的Meta分析

目的系统评价ABCB1基因C3435T多态性对他汀类药物降脂疗效的影响。方法计算机检索PubMed、Web of Science、the Cochrane Library、中国知网和维普网,收集患者使用他汀类药物的队列研究,检索时限为建库至2023年11月1日。筛选文献、提取数据、评价质量后,采用RevMan 5.4软件进行Meta分析。结果共纳入11项文献,共计1575例患者。Meta分析结果显示,显性遗传模型下,CT+TT型患者的低密度脂蛋白胆固醇(LDL-C)降低程度[MD=-1.87,95%CI(-3.62,-0.13),P=0.04]、总胆固醇(TC)降低程度[MD=-1.42,95%CI(-2.80,-0.04),P=0.04]均显著高于CC型;CT+TT型患者的高密度脂蛋白胆固醇(HDL-C)升高程度[MD=-0.65,95%CI(-2.48,1.18),P=0.49]、甘油三酯(TG)降低程度[MD=-0.05,95%CI(-2.94,2.84),P=0.97]与CC型比较,差异均无统计学意义。隐性遗传模型下,TT型患者的TC降低程度[MD=2.26,95%CI(0.97,3.56),P=0.0006]、HDL-C升高程度[MD=2.38,95%CI(0.42,4.35),P=0.02]均显著高于CC+CT型;CC+CT型患者的LDL-C降低程度[MD=1.53,95%CI(-0.10,3.15),P=0.07]、TG降低程度[MD=0.06,95%CI(-2.98,3.10),P=0.97]与TT型比较,差异均无统计学意义。加性遗传模型下,TT型患者的TC降低程度[MD=2.98,95%CI(1.27,4.69),P=0.0006]、LDL-C降低程度[MD=2.84,95%CI(0.67,5.01),P=0.01]均显著高于CC型;TT型患者的HDL-C升高程度[MD=2.40,95%CI(-0.17,4.97),P=0.07]、TG降低程度[MD=0.97,95%CI(-2.93,4.87),P=0.63]与CC型比较,差异均无统计学意义。结论血脂异常患者接受他汀类药物治疗时,LDL-C、TC降低效果可能与ABCB1基因C3435T杂合和纯合突变有关,即与CC型患者比较,CT或TT型患者的LDL-C、TC降低效果可能更明显;HDL-C升高效果可能与纯合突变有关,即与CC+CT型患者比较,TT型患者的HDL-C升高效果可能更明显;而TG变化可能与ABCB1基因C3435T多态性无关。

丁苯酞联合他汀类降脂药治疗急性脑梗死的疗效及安全性分析

目的:探讨丁苯酞联合他汀类降脂药治疗急性脑梗死的疗效及安全性。方法:选取医院收治的70例急性脑梗死患者,随机分为观察组(35例,采用丁苯酰联合他汀类降脂药以及基础治疗)和对照组(35例,采用西医常规治疗联合他汀类降脂药治疗),对比两组患者总有效率、治疗前后炎症反应状况和神经功能评分改善情况、用药不良反应发生率。结果:观察组患者治疗总有效率明显高于对照组(P<0.05),炎症反应状况和神经功能评分改善情况明显优于对照组(P<0.05);两组患者不良反应发生率的差异无统计学意义(P0.05)。结论:丁苯酰联合他汀类降脂药治疗急性脑梗死具有良好的疗效及较高的安全性。

他汀类与抗血小板聚集药物联合应用于缺血性脑血管病治疗中的效果分析

目的分析他汀类与抗血小板聚集药物联合应用于缺血性脑血管病治疗中的效果。方法104例缺血性脑血管病患者,根据就诊日期单双号分为对照组和联合组,每组52例。对照组应用抗血小板聚集药物治疗,联合组应用他汀类与抗血小板聚集药物联合治疗。比较两组患者治疗前后美国国立卫生研究院卒中量表(NIHSS)评分、Barthel指数、血脂指标[甘油三酯(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)]、C反应蛋白(CRP)水平、内膜中层厚度(IMT)及临床效果。结果治疗后,联合组患者NIHSS评分(8.73±3.46)分低于对照组的(14.02±4.21)分,Barthel指数(72.72±7.53)分高于对照组的(54.86±6.33)分(P<0.05)。治疗后,联合组患者TG(1.21±0.34)mmol/L、TC(2.70±0.22)mmol/L、LDL-C(1.57±0.38)mmol/L低于对照组的(1.59±0.52)、(3.63±0.58)、(2.12±0.49)mmol/L,HDL-C(1.86±0.72)mmol/L高于对照组的(1.59±0.48)mmol/L(P<0.05)。治疗后,联合组患者CRP(2.07±0.39)mg/L、IMT(0.63±0.14)mm低于对照组的(5.46±1.26)mg/L、(0.85±0.19)mm(P<0.05)。联合组临床总有效率为94.23%,高于对照组的80.77%(P<0.05)。结论缺血性脑血管病治疗中采用他汀类和抗血小板聚集类药物联合治疗可提高神经功能、日常生活能力,改善血脂水平,从而帮助患者获得更为满意的疗效和预后。

特发性膜性肾病患者脂代谢对免疫抑制剂联合糖皮质激素治疗效果的影响

目的探讨特发性膜性肾病患者脂代谢对免疫抑制剂联合糖皮质激素治疗效果的影响。方法86例行免疫抑制剂联合糖皮质激素治疗的特发性膜性肾病患者根据治疗效果分为未好转组和好转组,比较两组的基线资料和脂代谢指标,分析治疗效果的相关影响因素。结果治疗6个月后,86例特发性膜性肾病患者中16例未好转,占比18.60%。未好转组的TC、TG水平高于好转组(P<0.05)。Logistic回归分析显示,TC、TG水平是特发性膜性肾病患者免疫抑制剂联合糖皮质激素治疗效果的影响因素(OR>1,P<0.05)。结论特发性膜性肾病患者的脂代谢水平会对免疫抑制剂联合糖皮质激素的治疗效果产生影响。

孕激素与短效口服避孕药治疗青春期多囊卵巢综合征的效果及对患者性激素、糖脂代谢和情绪状态的影响

目的 分析孕激素与短效口服避孕药治疗青春期多囊卵巢综合征(PCOS)的效果及对患者性激素、糖脂代谢和情绪状态的影响。方法 前瞻性选取2022年1月至2023年6月在秦皇岛市妇幼保健院就诊的192例青春期PCOS患者作为研究对象,按照随机数字表法将其分为孕激素组和避孕药组,每组各96例。孕激素组患者给予周期性口服地屈孕酮片,避孕药组患者给予口服屈螺酮炔雌醇片。两组患者均同时给予调整生活方式、控制体重和口服盐酸二甲双胍治疗,均连续治疗3个月经周期。比较两组患者的临床疗效及治疗前和治疗后的血清性激素[卵泡刺激素(FSH)、黄体生成素(LH)、睾酮、雄烯二酮、雌二醇]水平、糖脂代谢指标[空腹血糖、空腹胰岛素(FINS)、HOMA-IR、甘油三酯、总胆固醇、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)]、抑郁自评量表(SDS)评分和焦虑自评量表(SAS)评分;并记录两组患者治疗期间的不良反应发生情况。结果 两组患者疗效分布和临床有效率比较差异均无统计学意义(P>0.05)。避孕药组患者治疗后的血清睾酮、雄烯二酮水平分别为(29.15±4.23)、(1.23±0.43) nmol/L,均低于孕激素组[(37.76±4.85)、(1.86±0.56) nmol/L],差异均有统计学意义(P<0.05),而两组患者治疗后FSH、LH、雌二醇水平比较,差异均无统计学意义(P>0.05)。避孕药组患者治疗后的血清HDL-C水平为(1.84±0.28) mmol/L,高于孕激素组[(1.70±0.23) mmol/L],差异有统计学意义(P<0.05),而两组患者治疗后其他糖脂代谢指标比较,差异均无统计学意义(P>0.05)。避孕药组患者治疗后的SDS评分、SAS评分分别为(50.31±5.53)、(50.08±5.25)分,均低于孕激素组[(56.06±6.02)、(57.63±6.00)分],差异均有统计学意义(P<0.05)。在治疗过程中,避孕药组患者的总不良反应发生率为19.79%,高于孕激素组(8.33%),差异有统计学意义(P<0.05)。结论 在青春期PCOS治疗中,单独应用孕激素与短效避孕药在临床疗效和降低雌激素水平、缓解胰岛素抵抗方面的效果基本相当,短效避孕药治疗方案在纠正高雄激素血症、提升HDL-C水平和缓解负性情绪方面的作用更加显著,但可能增加治疗的不良反应,临床需要根据患者的实际情况进行合理决策。